Pioglitazone 30 mg

DRUG12 trials

Conditions

Androgen DeficiencyBreast CancerDiabete MellitusDiabetes MellitusDiabetes Mellitus, Type 2GastroparesisInsulin ResistanceMuscle Fatigue

Early Phase 1

Pioglitazone for Idiopathic Gastroparesis

CompletedNCT04300127

Johns Hopkins UniversityGastroparesis

Start: 2019-10-24End: 2025-03-18Updated: 2025-04-30

Phase 1

A Study to Evaluate the Pharmacokinetics and Safety Between BR3006 and Co-administration of BR3006A, BR3006B, and BR3006C in Healthy Adult Volunteers (Fed)

RecruitingNCT07083401

Boryung Pharmaceutical Co., LtdDiabete Mellitus

Start: 2025-07-05End: 2026-07-05Target: 40Updated: 2025-07-24

A Study to Evaluate the Pharmacokinetics and Safety Between BR3006 and Co-administration of BR3006A, BR3006B, and BR3006C in Healthy Adult Volunteers (Fasting)

RecruitingNCT07083388

Boryung Pharmaceutical Co., LtdDiabetes Mellitus

Start: 2025-07-03End: 2026-07-03Target: 52Updated: 2025-07-24

Phase 2

A Study of Multiple Oral Doses of JNJ-41443532 in Patients With Type 2 Diabetes Mellitus

CompletedNCT01230749

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Diabetes Mellitus, Type 2

Start: 2010-12-31End: 2011-06-30Updated: 2013-12-11

Insulin Resistance and Androgen Deprivation Therapy

WithdrawnNCT04995978

St. Louis UniversityInsulin Resistance, Prostate Cancer

Start: 2021-12-01End: 2023-01-18Updated: 2023-06-23

Pioglitazone Therapy Targeting Fatigue in Breast Cancer

RecruitingNCT05013255

West Virginia UniversityBreast Cancer, Muscle Fatigue

Start: 2021-12-23End: 2026-12-31Target: 30Updated: 2025-04-08

Efficacy and Safety of Dapagliflozin in Patients with Non-alcoholic Steatohepatitis

CompletedNCT05254626

Cairo UniversityNon-alcoholic Steatohepatitis

Start: 2022-08-01End: 2024-07-23Updated: 2024-09-19

Phase 3

30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks

CompletedNCT01183013

Boehringer IngelheimDiabetes Mellitus, Type 2

Start: 2010-08-31End: 2013-02-28Updated: 2014-10-20

Sitagliptin vs. Pioglitazone as add-on Treatments in Patients With Type 2 Diabetes Uncontrolled on the Full-dose Metformin Plus Sulfonylurea

CompletedNCT03125694

Tehran University of Medical SciencesUncontrolled Type 2 Diabetes Mellitus

Start: 2015-02-01End: 2017-04-01Updated: 2017-04-24

A Study to Evaluate the Efficacy and Safety of Pioglitazone 15mg or 30mg Add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin

CompletedNCT04885712

Boryung Pharmaceutical Co., LtdType2 Diabetes

Start: 2021-05-28End: 2023-03-10Updated: 2023-05-24

Pioglitazone and Insulin Resistance in ADT

WithdrawnNCT05098327

State University of New York at BuffaloAndrogen Deficiency, Diabetes Mellitus, Type 2, Insulin Resistance +1

Start: 2021-08-01End: 2023-03-31Updated: 2023-08-15

Phase 4

Clinical Trial of Pioglitazone Treatment in Patients With Type 2 Diabetes Mellitus and Covid-19

CompletedNCT04535700

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y CajalType 2 Diabetes

Start: 2020-09-18End: 2022-01-10Updated: 2023-05-31

Related Papers

Efficacy and safety of dapagliflozin compared to pioglitazone in diabetic and non-diabetic patients with non-alcoholic steatohepatitis: A randomized clinical trial.

2025-01-293 citations

NAFLD and NAFLD Related HCC: Emerging Treatments and Clinical Trials.

2025-01-019 citations

Efficacy and Safety of Pioglitazone Add-on in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin and Dapagliflozin: A Multicenter, Randomized, Double-blind, and Placebo-controlled Study.

2024-07-268 citations

From cause to consequence: Insights into incident diabetes mellitus after hepatic steatosis

Clinical Liver Disease2023-01-132 citations